Top Abstract Purchase Related
Home
>
Node
>
Subnode

Economic evaluation of a new treatment for rheumatoid arthritis

Suka, M.; Yoshida, K.

Nihon Rinsho. Japanese Journal of Clinical Medicine 65(7): 1327-1330

2007

ISSN/ISBN: 0047-1852
PMID: 17642251
Document Number: 606866
In recent years, new biologic agents have been approved for the treatment of rheumatoid arthritis. These agents may yield clear clinical benefits but impose greater costs than standard treatment. Economic evaluations have been used to provide evidence for the cost-effectiveness of treatment. We described two approaches to the cost-effectiveness analysis of the treatment of rheumatoid arthritis-micro-level economic evaluation based on quality-adjusted life years (QALYs) and macro-level economic evaluation based on disability-adjusted life years (DALYs).

Document emailed within 1 workday
Secure & encrypted payments

Henrard, J.C.; Bennett, P.H.; Burch, T.A. 1974: Epidemiology of rheumatoid arthritis. Evaluation of the so-called Rome and new York criteria for the diagnosis of rheumatoid arthritis in a population study Revue du Rhumatisme et des Maladies Osteo-Articulaires 41(11): 675-683
Yamanaka, H. 2018: Diagnosis and treatment of rheumatoid arthritis:toward the best practice. how to use the guideline in the management of rheumatoid arthritis Clinical Calcium 28(5): 607-610
Suzuki, K.; Takeuchi, T. 2018: Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Towards precision medicine in rheumatoid arthritis Clinical Calcium 28(5): 626-629
Martínez, R.O.; Casas, H.; Mazure, P.A.; Leczycki, H.; Cosen, J.N.; Canievsky, L.; Abib, A. 1988: Gastroduodenal lesions in rheumatoid arthritis. Evaluation and treatment Acta Gastroenterologica Latinoamericana 18(2): 87-96
Shiokawa, Y.; Abe, T.; Onoda, T. 1974: Evaluation of 19583RP (ketoprofen) in the treatment of chronic rheumatoid arthritis Ryumachi 14(3): 279-286
Azuma, T.; Sugawara, S.; Maeda, A.; Miyauchi, T.; Aritomi, H. 1986: Long-term comparative studies on gold, D-penicillamine, and NSAIDs for the treatment of early rheumatoid arthritis. 1. Evaluation of one year's treatment Ryumachi 26(3): 200-209
Shiokawa, Y.; Horiuchi, T.; Honma, M.; Kageyama, T.; Okada, T. 1977: Clinical evaluation of D-penicillamine for the treatment of rheumatoid arthritis by a double blind test Ryumachi 17(2): 205-210
Grekhov, R.A.; Aleksandrov, A.V.; Kedrov, V.L.; Zborovskiĭ, A.B. 2008: The evaluation of the quality of life as a criterion of the efficiency of rehabilitating treatment in rheumatoid arthritis Klinicheskaia Meditsina 86(7): 39-42
Dougados, M. 1990: Proposed guidelines for the clinical evaluation of interleukin-1 inhibitors in the treatment of rheumatoid arthritis European Cytokine Network 1(4): 235-237
Gómez Rodríguez, N. 2003: Socio-economic repercussion of rheumatoid arthritis Anales de Medicina Interna 20(3): 111-113
Yasuda, S. 2018: Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice in the use of T cell co-stimulatory inhibitor for patients with rheumatoid arthritis Clinical Calcium 28(5): 668-676
Furst, D.E.; Schiff, M.H.; Fleischmann, R.M.; Strand, V.; Birbara, C.A.; Compagnone, D.; Fischkoff, S.A.; Chartash, E.K. 2003: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) Journal of Rheumatology 30(12): 2563-2571
Dadoun, S.; Fautrel, B. 2012: Medico-economic aspects of management of patients with rheumatoid arthritis La Revue du Praticien 62(8): 1116-1117
Di Matteo, L.; D'Incecco, V.; Evangelista, L.; Castiglione, C.; Consoli, G. 1985: Evaluation of lymphocyte subpopulations using monoclonal antibodies in patients with rheumatoid arthritis undergoing treatment with a new gold salt (auranofin) Bollettino della Societa Italiana di Biologia Sperimentale 61(5): 777-781
Kavanaugh, A.; Han, C.; Bala, M. 2004: Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis Journal of Rheumatology 31(5): 849-855
Revaz, S.; Dudler, J. 2008: Diagnosis and treatment of rheumatoid vasculitis and other systemic complications of rheumatoid arthritis Revue Medicale Suisse 4(149): 712; 714 716-717
Langdon, C.G.; Moran, D.G.; Jamieson, V.; Spence, S.; Hill, S.A. 1990: A multicentre study of tenoxicam for the treatment of osteo-arthritis and rheumatoid arthritis in general practice Journal of International Medical Research 18(6): 489-496
Marhoffer, W.; Schatz, H.; Stracke, H.; Ullmann, J.; Schmidt, K.; Federlin, K. 1991: Serum osteocalcin levels in rheumatoid arthritis: a marker for accelerated bone turnover in late onset rheumatoid arthritis Journal of Rheumatology 18(8): 1158-1162
Barrera, P.; Balsa, A.; Alves, H.; Westhovens, R.; Maenaut, K.; Cornélis, F.; Fritz, P.; Bardin, T.; Ceu Maia, M.; Lopes-Vaz, A.; Pascual Salcedo, D.; de la Concha, E.; Radstake, T.; van de Putte, L.B.; Migliorini, P.; Prudhomme, J.F.; Charron, D.; Spyropoulou, M.; Mendes, A.; Spaepen, M.; Martinez, M.; Stavropoulos, C. 2001: Noninherited maternal antigens do not increase the susceptibility for familial rheumatoid arthritis. European Consortium on Rheumatoid Arthritis Families (ECRAF) Journal of Rheumatology 28(5): 968-974
Jaller Char, J.J.; Jaller, J.A.; Waibel, J.S.; Bhanusali, D.G.; Bhanusali, N. 2018: The Role of IL-17 in the Human Immune System and its Blockage as a Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Journal of Drugs in Dermatology: Jdd 17(5): 539-542